Aldesleukin Completed Phase 1 Trials for Cytomegalovirus Retinitis / Human Immunodeficiency Virus (HIV) Infections Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00000680A Phase I Study of Autologous, Activated CD8(+) Lymphocytes Expanded In Vitro and Infused With or Without Recombinant Interleukin-2 to Patients With AIDS or Severe ARC
NCT00000728Phase I Trial of the Combination of Zidovudine and Recombinant Interleukin-2 in Patients With Persistent Generalized Lymphadenopathy
NCT00002321A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis
NCT00001005A Study of Zidovudine Plus Interleukin-2 in HIV-Infected Patients Who Have No Symptoms of Infection But Who Have Tender Lymph Nodes
NCT00000986The Safety and Effectiveness of Interleukin-2 Plus Zidovudine in Patients With AIDS or AIDS Related Complex
NCT00000821Subcutaneously Administered Aldesleukin ( Interleukin-2; IL-2 ) Therapy in HIV-Infected Patients
NCT00000849A Study to Test the Safety of Recombinant Interleukin-2 (rIL-2) in HIV-Infected Children
NCT00110578Safety and Effectiveness of Immunotherapy With Autologous HIV-Specific CD8 Cells in HIV Infected Adults
NCT00006066Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems
NCT00002107A Phase I Study of Subcutaneously Administered Proleukin (Aldesleukin) in HIV-Infected Patients